Gilead Sciences, INC Form 4 insider transactions

Gilead Sciences CFO Andrew D. Dickinson reported the vesting of restricted stock units, a new grant of RSUs and stock options, and a related tax withholding sale.

Gilead Sciences' Chief Communications and Corporate Affairs Officer, Johanna Mercier, reported the acquisition of new restricted stock units and stock options, alongside common stock transactions.

Gilead Sciences EVP Keeley M. Cain Wettan reported acquisition of common stock, restricted stock units, and non-qualified stock options, alongside a tax-related disposal of shares.

Erin Burkhart, SVP of Controllership at Gilead Sciences, Inc., was granted 2,355 restricted stock units and 5,455 non-qualified stock options.

Gilead Sciences CEO Daniel O'Day reported multiple equity transactions, including RSU vesting, stock sales for tax, and new RSU and stock option grants.

Gilead Sciences' Chief Medical Officer, Dietmar Berger, reported the acquisition of common stock and new equity incentives, alongside the sale of shares.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, acquired 11,090 shares of common stock through the vesting of performance share awards.

Gilead Sciences' Chief Communications and Corporate Affairs Officer, Johanna Mercier, acquired 11,090 shares of common stock through the vesting of performance share awards.

Gilead Sciences' Chief Medical Officer, Dietmar Berger, saw 8,530 performance-based common stock shares vest after meeting specific performance goals.

Gilead Sciences' EVP and General Counsel, Keeley M. Cain Wettan, acquired 470 shares of common stock through the vesting of performance share awards.

Gilead Sciences Chairman & CEO Daniel O'Day reported the vesting of performance shares and subsequent sales of common stock under a pre-arranged trading plan.

Gilead Sciences Chairman and CEO Daniel P. O'Day exercised stock options and subsequently sold an equal number of shares under a pre-arranged trading plan.

Gilead Sciences' Chief Communications and Corporate Affairs Officer, Johanna Mercier, reported the acquisition of performance-vested shares and a related disposition for tax purposes.

Gilead Sciences CFO Andrew D. Dickinson reported the vesting of performance share awards and a related tax withholding transaction.

Gilead Sciences CEO Daniel O'Day reported the acquisition of 131,675 common shares from performance awards and the disposition of 74,461 shares for tax purposes.

Gilead Sciences' Chairman and CEO, Daniel P. O'Day, reported the sale of 10,000 shares of common stock on January 28, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences CEO Daniel O'Day exercised stock options and subsequently sold shares totaling over $15.6 million, executed under a pre-arranged 10b5-1 trading plan.

Gilead Sciences Director Jeffrey Bluestone exercised stock options and sold 5,000 shares of common stock for $123.50 per share under a pre-arranged trading plan.

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock for $124.31 per share on January 15, 2026, under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, filed a Form 4 disclosing a planned sale of 3,000 shares of common stock in January 2026 under a Rule 10b5-1 plan.

Gilead Sciences' Chief Medical Officer, Dietmar Berger, reported the vesting and subsequent sale of shares from restricted stock units.

Gilead Sciences Chairman and CEO Daniel O'Day sold 10,000 shares of common stock for approximately $1.25 million, executed under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock for $122 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, reported the sale of 3,000 shares of common stock at $122 per share, executed under a pre-arranged 10b5-1 trading plan.

Gilead Sciences CFO Andrew D. Dickinson reported the vesting of restricted stock units and subsequent sale of shares for tax obligations, a routine insider transaction.

Gilead Sciences Chairman & CEO Daniel P. O'Day exercised 10,426 restricted stock units and sold 4,931 shares of common stock to cover tax liabilities.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, reported the acquisition of common stock through RSU conversion and subsequent sale of shares for tax obligations.

Gilead Sciences Director Kelly A. Kramer exercised stock options and subsequently sold common stock under a Rule 10b5-1 trading plan.

Gilead Sciences Director Jeffrey Bluestone exercised 5,000 stock options and simultaneously sold the acquired shares for a profit on November 28, 2025.

Gilead Sciences CEO Daniel O'Day sold 10,000 shares of common stock on November 28, 2025, under a pre-arranged Rule 10b5-1 trading plan.